The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tofacitinib Shows Ongoing Action Against Plaque Psoriasis

Tofacitinib Shows Ongoing Action Against Plaque Psoriasis

March 3, 2016 • By David Douglas

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) shows long-term efficacy against chronic plaque psoriasis, according to findings from two randomized studies and an extension trial.

You Might Also Like
  • Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis
  • Tofacitinib Treatment May Improve Nail Psoriasis
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis

The outcome, Dr. Svitlana Tatulych told Reuters Health by email, “demonstrated that oral tofacitinib, at both the 10 mg and 5 mg twice-daily doses, provided sustained efficacy in patients with moderate to severe chronic plaque psoriasis out to two years.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a Feb. 20 online paper in the Journal of the American Academy of Dermatology, Dr. Tatulych, of Pfizer, Groton, Conn., and colleagues noted that previous studies have shown the efficacy and safety of continuous tofacitinib treatment vs. placebo over 16 weeks.

To extend these findings, the researchers conducted two identical placebo-controlled Phase 3 studies in more than 1,800 patients with a diagnosis of plaque-type psoriasis for at least 12 months.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At week 16, all placebo patients were rerandomized to tofacitinib and followed up to 52 weeks. Eligible patients then entered an ongoing long-term extension study.

After 28 weeks, 55.6% of the patients in the 5 mg active treatment group and 68.8% of those in the 10 mg group had a 75% or greater reduction in Psoriasis Area and Severity Index score from baseline. Corresponding proportions for Physician Global Assessment of clear or almost clear were 54.7% and 65.9%.

There were no unexpected safety findings. Rates of serious adverse events (SAEs) and discontinuations because of adverse events (AEs) were low (less than 6%) and similar between tofacitinib doses through week 52.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“The most common AEs,” continued Dr. Tatulych, “were nasopharyngitis and upper respiratory tract infection. Safety events were also reported for the total tofacitinib exposure to describe the longer-term safety profile.”

“Over 33 months,” she said, “10.1% of patients experienced SAEs and 10.7% of patients discontinued because of AEs. The most common AEs remained nasopharyngitis and upper respiratory tract infection.”

These data, the investigators concluded, “support the continued evaluation of tofacitinib as a potential new, long-term, oral treatment option for plaque psoriasis.”

Pfizer sponsored this research. Dr. Tatulych and a number of other authors are employed by or have relationships with the company.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Janus Kinase Inhibitors, plaque psoriasis, Tofacitinib

You Might Also Like:
  • Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis
  • Tofacitinib Treatment May Improve Nail Psoriasis
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.